stockrow
Friday 6 November 2026
Export OPK’s income statement to Excel — free account
OPKO Health, Inc.
OPK Healthcare Diagnostics & Research
- Revenue
- −56.9%
- EPS
- −333.3%
- Free cash flow
- −3.40%
- Total debt
- +40.7%
Quarter to September 2026, against a year earlier
1.79
0.04
+2.29%
Follow OPK
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1,117 | 966 | 990 | 902 | 1,435 | 1,775 | 1,004 | 863 | 713 | 607 | 502 | (6.6%) | 570 | 495 | 606 | (0.1%) | |
| Gross margin, % | 45.28 | 35.80 | 38.94 | 36.53 | 37.69 | 32.77 | 28.70 | 36.84 | 30.64 | 33.93 | 46.22 | (11.3) pt | ||||||
| EBT | (97) | (272) | (177) | (305) | 49 | (14) | (392) | (184) | (10) | (241) | (159) | +10.7% | ||||||
| EBT margin, % | (8.66) | (28.15) | (17.90) | (33.81) | 3.39 | (0.79) | (38.99) | (21.35) | (1.45) | (39.77) | (31.72) | (31.1) pt | ||||||
| Net income | (48) | (305) | (153) | (315) | 31 | (30) | (328) | (189) | (53) | (226) | (148) | +18.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 2.03 | 1.73 | 1.76 | 1.51 | 2.24 | 2.74 | 1.40 | 1.15 | 1.03 | 0.81 | 0.67 | (9.7%) | |||||
| Earnings | (0.09) | (0.55) | (0.27) | (0.53) | 0.05 | (0.05) | (0.46) | (0.25) | (0.08) | (0.30) | (0.19) | +14.6% | ||||||
| Cash flow | 0.06 | (0.16) | (0.19) | (0.29) | 0.06 | 0.06 | (0.13) | (0.04) | (0.26) | (0.24) | (0.17) | n/m | ||||||
| Capex | (0.04) | (0.07) | (0.05) | (0.02) | (0.05) | 0.05 | (0.03) | (0.02) | (0.04) | (0.02) | (0.01) | (9.7%) | ||||||
| Free cash flow | 0.02 | (0.23) | (0.24) | (0.31) | 0.01 | 0.11 | (0.16) | (0.06) | (0.30) | (0.25) | (0.18) | n/m | ||||||
| Book value | 3.80 | 3.30 | 3.18 | 2.71 | 2.61 | 2.60 | 2.17 | 1.85 | 1.97 | 1.69 | 1.50 | (8.6%) | ||||||
| Shares, m | 551 | 559 | 563 | 595 | 641 | 648 | 719 | 752 | 694 | 751 | 753 | +3.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 79.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.9 | |||||
| P/S | 4.48 | 2.88 | 1.71 | 0.97 | 1.76 | 1.76 | 0.87 | 1.37 | 1.43 | 1.56 | 2.60 | 1.9 | ||||||
| P/B | 2.39 | 1.51 | 0.95 | 0.54 | 1.51 | 1.85 | 0.56 | 0.85 | 0.75 | 0.75 | 1.17 | 1.2 | ||||||
| EV/Sales | 4.38 | 2.82 | 1.71 | 1.12 | 1.89 | 1.79 | 0.97 | 1.54 | 1.43 | 1.51 | 2.77 | 1.9 | ||||||
| EV/FCF | 998.81 | (19.31) | (11.62) | (5.19) | (685.78) | 51.20 | (7.60) | (25.62) | (4.68) | (4.58) | (9.58) | 28.6 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 32 | (92) | (109) | (173) | 39 | 38 | (95) | (28) | (183) | (179) | (125) | n/m | |||||
| Capex | (22) | (39) | (27) | (12) | (33) | 34 | (23) | (14) | (25) | (12) | (10) | (6.6%) | ||||||
| Free cash flow | 10 | (131) | (136) | (185) | 6 | 72 | (118) | (42) | (208) | (191) | (135) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 220 | 37 | 29 | 75 | 148 | 493 | 181 | 109 | 469 | 435 | 644 | +7.9% | |||||
| Net debt | (113) | (50) | (2) | 135 | 186 | 68 | 94 | 146 | 2 | (27) | 72 | (14.6%) | ||||||
| Shareholders’ equity | 2,092 | 1,844 | 1,791 | 1,615 | 1,672 | 1,685 | 1,562 | 1,389 | 1,365 | 1,268 | 1,116 | (5.4%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (1.74) | (11.40) | (6.07) | (13.23) | 1.28 | (1.24) | (14.38) | (9.04) | (2.53) | (10.92) | (7.64) | (9.2) pt | |||||
| ROIC | (3.05) | (9.64) | (5.98) | (9.79) | 1.94 | 0.67 | (8.54) | (6.39) | (6.95) | (5.91) | (6.72) | (2.9) pt | ||||||
| ROE | (2.38) | (15.51) | (8.42) | (18.49) | 1.86 | (1.80) | (20.23) | (12.80) | (3.86) | (17.14) | (12.23) | (14.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 6,041 | 6,030 | 5,690 | 6,096 | 5,269 | 5,767 | 4,196 | 3,930 | 2,997 | 1,373 | — | (15.2%) | |||||
| Revenue/emp, $m | 0.18 | 0.16 | 0.17 | 0.15 | 0.27 | 0.31 | 0.24 | 0.22 | 0.24 | 0.44 | — | +10.2% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026
OPKO Health, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NEO NeoGenomics, Inc. | $2.1B | — (loss-making) | — (loss-making) | +11.43% (above 0%: growing) | n/m | −3,724.21% (below 0%: shrinking) | 46.16% | (3.79%) | Compare |
| VCYT Veracyte, Inc. | $1.9B | 15.2× | 45.2× | +15.08% (above 0%: growing) | +62.50% (above 0%: growing) | −9.63% (below 0%: shrinking) | 70.58% | 10.92% | Compare |
| WGS GeneDx Holdings Corp. | $1.9B | — (loss-making) | — (loss-making) | +11.44% (above 0%: growing) | n/m | −585.59% (below 0%: shrinking) | 68.37% | (15.25%) | Compare |
| PSNL Personalis, Inc. | $1.7B | — (loss-making) | — (loss-making) | +76.59% (above 0%: growing) | n/m | −15.54% (below 0%: shrinking) | 25.67% | (138.76%) | Compare |
| OPK OPKO Health, Inc. | $1.3B | — (loss-making) | — (loss-making) | −56.87% (below 0%: shrinking) | n/m | −3.40% (below 0%: shrinking) | 64.30% | (48.02%) | |
| FRNM Freenome, Inc | $1.1B | — (loss-making) | — | — | n/m | +12.06% (above 0%: growing) | — | 0.00% | Compare |
| CSTL Castle Biosciences, Inc. | $1.0B | — (loss-making) | — (loss-making) | +23.90% (above 0%: growing) | n/m | +56.82% (above 0%: growing) | 76.75% | (2.65%) | Compare |
| MYGN Myriad Genetics, Inc. | $601.6M | — (loss-making) | — (loss-making) | −10.51% (below 0%: shrinking) | n/m | +43.90% (above 0%: growing) | 66.60% | (20.40%) | Compare |
| FLGT Fulgent Genetics, Inc. | $513.4M | — (loss-making) | — (loss-making) | +7.54% (above 0%: growing) | n/m | +2,058.74% (above 0%: growing) | 35.33% | (24.94%) | Compare |
| Median of peers | $1.4B | — | — | +11.44% | — | +1.22% | 66.60% | (9.52%) |
Pay and ownership Proxy statement filed 30 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.85m | 1.34m | 31.90 |
| 2024 | 2.16m | 2.02m | 37.22 |
| 2023 | 2.28m | 2.17m | 38.23 |
| 2022 | 972.20k | (1.25m) | 31.66 |
| 2021 | 2.10m | 2.40m | 121.77 |
Ownership
Directors and executive officers, together
44.72% of Common Stock
Phillip Frost, M.D.
33.31% of Common Stock
Frost Gamma Investments Trust
28.70% of Common Stock
Rubric Capital Management LP
6.33% of Common Stock
Bruce C. Holbrook
5.35% of Common Stock
Coe M. Magruder
5.27% of Common Stock
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement